EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Inhibition of NHE1 Overcomes Temozolomide‐Resistance in Glioblastoma via ROS‐AKT/ERK Axis‐Mediated Autophagy Suppression

Dan Li iD, Yuhui Li, Xuan Zheng, Zhuo Wang, Yang Wang, Jun Zhang, Jianxiong Guo, Lei Wang, Jingwu Li, Yongliang Liu, Yufeng Li iD

Journal of Biochemical and Molecular Toxicology · 2026

DOI: 10.1002/jbt.71110 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, 2026. Verfasst von Dan Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Hebei Key Laboratory of Molecular Oncology, Tangshan People's Hospital, Hebei, China. Hauptthemen laut MEDLINE: Temozolomide, Sodium-Hydrogen Exchanger 1, Glioblastoma, Reactive Oxygen Species. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Planning Project Fund of Tangshan, the Key Discipline Fund of Tangshan, the Medical Science Research Program of Hebei Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GBM) is the most aggressive primary brain tumor in adults, with temozolomide (TMZ) resistance being a major barrier to improved clinical outcomes. Dysregulated autophagy is closely associated with TMZ resistance in GBM, but the role of sodium/hydrogen exchanger 1 (NHE1)—a key regulator of intracellular pH homeostasis—in this process remains uncharacterized. We established a TMZ‐resistant GBM cell line (U251TR) and observed that U251TR cells displayed higher autophagic activity, increased reactive oxygen species (ROS) levels, and reduced apoptotic rates compared to parental U251 cells. Treatment with the NHE1‐specific inhibitor HOE‐642 dose‐dependently suppressed cell viability, inhibited NHE1 activity, reduced intracellular ROS production, and promoted apoptosis in U251TR cells, with a positive feedback loop identified between NHE1 and ROS. Mechanistically, HOE‐642 blocked autophagic initiation and flux primarily via the ROS‐AKT/ERK signaling axis, in which reduced ROS downregulated p‐AKT and p‐ERK1/2, where ERK exerted pro‐autophagic effects and AKT exerted anti‐autophagic effects. In vivo, combined HOE‐642 and TMZ treatment significantly reduced xenograft tumor volume and weight, inhibited autophagy, and activated apoptosis compared to TMZ monotherapy, without causing evident systemic toxicity. Our findings identify a novel NHE1‐ROS‐AKT/ERK‐autophagy regulatory axis in TMZ‐resistant GBM, validating NHE1 as a potential therapeutic target to enhance TMZ sensitivity by disrupting the autophagy‐apoptosis balance, and providing a new strategy for GBM treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TemozolomideSodium-Hydrogen Exchanger 1GlioblastomaReactive Oxygen SpeciesAutophagyDrug Resistance, NeoplasmProto-Oncogene Proteins c-aktBrain NeoplasmsMAP Kinase Signaling SystemHumansAnimalsCell Line, TumorMiceMice, NudeXenograft Model Antitumor AssaysAntineoplastic Agents, AlkylatingGuanidinesApoptosisSulfones

Stichwörter der Autor:innen

NHE1ROS‐AKT/ERK axisautophagyglioblastomatemozolomide resistance

Substanzen

TemozolomideSodium-Hydrogen Exchanger 1Reactive Oxygen SpeciesProto-Oncogene Proteins c-aktSLC9A1 protein, humancariporideAntineoplastic Agents, AlkylatingGuanidinesSulfones

Autor:innen und Institutionen

  • Hebei Key Laboratory of Molecular Oncology, Tangshan People's Hospital, Hebei, China.
  • Tangshan Key Laboratory of Cancer Prevention and Therapy, Tangshan People's Hospital, Hebei, China.
  • The Cancer Institute, Tangshan People's Hospital, Hebei, China.
  • Department of Neurosurgery, Tangshan People's Hospital, Tangshan, Hebei, China.
  • Department of Pathology, Tangshan People's Hospital, Hebei, China.
  • Department of Gastrointestinal Surgery, Tangshan People's Hospital, Hebei, China.

ORCID-Profile: Dan Li, Yufeng Li

Förderung

  • Science and Technology Planning Project Fund of Tangshan
  • the Key Discipline Fund of Tangshan
  • the Medical Science Research Program of Hebei Health Commission

Zitieren

APA

Li, D., Li, Y., Zheng, X., Wang, Z., Wang, Y., Zhang, J., Guo, J., Wang, L., Li, J., Liu, Y., & Li, Y. (2026). Inhibition of NHE1 Overcomes Temozolomide‐Resistance in Glioblastoma via ROS‐AKT/ERK Axis‐Mediated Autophagy Suppression. Journal of Biochemical and Molecular Toxicology. https://doi.org/10.1002/jbt.71110

Vancouver

Li D, Li Y, Zheng X, Wang Z, Wang Y, Zhang J, et al. Inhibition of NHE1 Overcomes Temozolomide‐Resistance in Glioblastoma via ROS‐AKT/ERK Axis‐Mediated Autophagy Suppression. Journal of Biochemical and Molecular Toxicology. 2026. doi:10.1002/jbt.71110

BibTeX
@article{Li2026,
  author = {Li, Dan and Li, Yuhui and Zheng, Xuan and Wang, Zhuo and Wang, Yang and Zhang, Jun and Guo, Jianxiong and Wang, Lei and Li, Jingwu and Liu, Yongliang and Li, Yufeng},
  title = {Inhibition of NHE1 Overcomes Temozolomide‐Resistance in Glioblastoma via ROS‐AKT/ERK Axis‐Mediated Autophagy Suppression},
  journal = {Journal of Biochemical and Molecular Toxicology},
  year = {2026},
  doi = {10.1002/jbt.71110}
}
Kostenlos starten →